GH1 and Creutzfeldt Jacob disease: The precise dates of starting and stopping treatment with any type of growth hormone were known for all but one patient; details of treatment with one product (Hartree modified Wilhelmi preparation), which is most implicated as the causative agent of iatrogenic CJD in the UK, were incomplete in two patients.